Multiple Sclerosis

The body's immune system can be "taught" not to attack its own cells, such as in the case of multiple sclerosis, according to research published in Nature Communications.

Doses of prepared human placenta culture cells are safe for multiple sclerosis patients, according to a study published in Multiple Sclerosis and Related Disorders.

Slow processing speed appears to explain executive deficits in multiple sclerosis patients, according to research published in Rehabilitation Psychology.

Patients with the relapsing-remitting form of multiple sclerosis have shown improvement with glatiramer acetate. Although it is unclear exactly how the drug works, recently published research has shed light on the ways in which glatiramer acetate affects B cells.

While multiple sclerosis (MS) has traditionally been thought of as being a T-cell mediated disease, an increasing body of evidence suggests that B cells and autoantibodies are involved in the pathology of MS, providing support for the use of treatments directed against B cells.

In secondary-progressive multiple sclerosis (SPMS), patients show worsening gait disorder and ambulatory dysfunction that require the use of a cane, a walker, or a wheelchair. Treatment options for SPMS are limited, but several new therapies show promise.

Adherence is defined as conforming to the recommendations made by the provider with respect to timing, dosage, and frequency of medication taking, and following these recommendations is important for patients with multiple sclerosis (MS) to fully benefit from disease-modifying therapies (DMTs).

Fumaric acid esters (FAEs) are a known component of a centuries-old herbal medicine, have been used for over 50 years as a topical treatment for psoriasis, and most recently, have demonstrated efficacy in treating relapsing- remitting multiple sclerosis.

Paul Wicks, PhD, discusses the surge in Internet-savvy patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Don Mahad, MD, PhD, discusses his research's focus of protecting nerve cells at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Alasdair Coles, MD, University of Cambridge, shares his thoughts on the efficacy of alemtuzumab for patients with multiple sclerosis (MS) at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.

Treatment with Sativex oromucosal spray produces significant reductions in spasticity in patients with multiple sclerosis (MS) compared with placebo, but researchers reported no significant difference between the two in neurophysiologic measures.

Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.

Patients treated for two years with a combination of glatiramer acetate and estriol experienced a one-third reduction in relapse rate compared with patients who received glatiramer acetate and placebo.

Patients with multiple sclerosis who received thrice-weekly injections of glatiramer acetate 40 mg/ml reported increased satisfaction with their treatment and experienced lower rates of moderate and severe injections site reactions and other adverse events.

Five-year data from the ENDORSE study shows that patients with multiple sclerosis who continued treatment, or who switched from another medication, experienced improved NEDA outcomes.

Mikkel Anthonisan, MD, highlights his experience as the founder of Oceans of Hope, a global voyage to change the perception of multiple sclerosis, at the 2014 Joint ACTRIMS-ECTRIMS Meeting.

Treatment with alemtuzumab was associated with reduced relapse rates and improved MRI outcomes compared to treatment with subcutaneous interferon beta-1a.

Novel drug shown to be more effective than interferon beta-1a in the treatment of multiple sclerosis, but concerns remain over hepatotoxicity, cutaneous reactions, and other adverse events associated with treatment.

A series of nurse-led interventions and patient education, along with titrated drug initiation, were the key components of a successful initiation protocol for patients with multiple sclerosis starting therapy on dimethyl fumarate. The new protocol resulted in fewer discontinuations than the standard initiation protocol.

Moderate disability due to multiple sclerosis could be treated with yoga, according to research from Rutgers investigators.

A version of injectable interferon that multiple sclerosis patients can use far less frequently than existing products is proving safe and effective in clinical trials, its manufacturer says. Biogen Idec announced that new data from the second year of its Phase III clinical trial of peginterferon beta-1a (Plegridy) show it is well tolerated and appears to halt symptoms of relapsing forms of MS. Patients getting the drug had a lower risk of relapse, less disability progression, and fewer new brain lesions than those who got a placebo.

When autoimmune diseases like multiple sclerosis attack a patient's body from the inside it can be a difficult reminder of how hard it can be to treat a condition from the inside out.

GeNeuro, a Swiss company specializing in promising therapies for neurological disorders, recently announced positive results from a Phase IIa study of a new drug for multiple sclerosis (MS).

Multiple sclerosis rates are rising in what are generally considered low-risk areas because of population and ethnicity changes, according to researchers.

There is no link between vitamin D levels in infancy to adult-onset multiple sclerosis, according to research conducted by the Karolinska Institutet in Sweden.

An investigational drug that researchers hope will reverse nerve damage in patients with multiple sclerosis (MS) has been found to be safe and well tolerated in early trials. The big question is whether it will work, researchers said.

The cannabis-based multiple sclerosis drug Sativex has been recommended for use in Wales, making it the first in the United Kingdom to do so. The drug awaits final approval from the government.

The autoimmune system may not be the primary location for multiple sclerosis development, according to a study published in Science Translational Medicine.